A bipartisan group of senators are asking the US FDA to make it easier for sponsors to develop generic versions of insulins even as the agency transitions regulation of the products from the NDA to BLA framework.
The letter (sent by Sens. Dick Durbin, D-Ill., Kevin Cramer, R-N.D., Tina Smith, D-Minn., and Bill Cassidy, R-La.) underscores...